Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First-of-its-Kind probiotic trial aims to tame autoimmune disease

NCT ID NCT06297213

Summary

This early-stage study is testing a new oral probiotic called R-2487 in people with Sjogren's Syndrome, an autoimmune disease. The main goal is to see if the probiotic is safe and well-tolerated. Researchers will also check if it helps reduce disease activity and improves patients' quality of life by measuring symptoms and inflammation.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.